deucravacitinib – Medxy AI

Targeting TYK2 with Deucravacitinib: Pharmacodynamic Insights from the Phase 2 PAISLEY Trial in Systemic Lupus Erythematosus

By MedXY 09/04/2026

Deucravacitinib, an oral selective TYK2 inhibitor, demonstrates significant suppression of interferon and B-cell pathway biomarkers in active SLE patients, supporting ongoing phase 3 trials for this challenging autoimmune disease.

Clinical Updates Dermatology news Specialties

Once-Daily Oral Icotrokinra vs Placebo and Deucravacitinib in Moderate-to-Severe Plaque Psoriasis: Insights from ICONIC-ADVANCE 1 & 2 Phase 3 Trials

By MedXY 10/10/2025

ICONIC-ADVANCE 1 & 2 phase 3 trials demonstrate that once-daily oral icotrokinra significantly improves skin clearance with superior efficacy and favorable safety compared to placebo and deucravacitinib in moderate-to-severe plaque psoriasis.

Allergy & Immunology Dermatology Specialties

Icotrokinra: A Promising Oral IL-23 Inhibitor Outperforms JAK Inhibitor in Psoriasis Phase 3 Trials

By MedXY 09/25/2025

In two phase 3 trials, oral IL-23 receptor inhibitor icotrokinra demonstrated superior efficacy and safety compared to the JAK inhibitor deucravacitinib in moderate-to-severe plaque psoriasis, marking a potential advancement in oral psoriasis therapies.